SEER is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
9 - Grade/differentiation unknown, not stated, or not applicable
Refractory neutropenia is characterized by >=10% dysplastic neutrophils in the peripheral blood or bone marrow; the dysplasia is principally manifest as nuclear hypolobation and hypogranulation.
(This code is effective for cases diagnosed 2010 and later. For cases diagnosed prior to 2010, see code 9989/3.)
Neutropenia secondary to drug therapy, toxic exposure, infectious processes, immune mechanisms, or other causative factors must be excluded. The other myeloid cell lines do not show significant dysplasia.
For MDS diseases (9980, 9982, 9983, 9985, 9986, 9989, 9991, 9992), abstracting each of the subtypes would result in over-counting of the diseases. 1, Code only the first subtype that is diagnosed. 2. Do not change the histology code or create a new abstract for any subsequent specific MDS subtypes.